Related Experiment Video
Updated: Jun 12, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Prognosis impact of multiple novel lymphocyte-based inflammatory indices in patients with initially diagnosed
Yi Gao1, Geng Bai1, Yuqing Li1
1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Insights
The novel Systemic Immune Inflammation Response Index (SIIRI) is a strong predictor of major adverse cardiovascular events (MACEs) in patients with coronary artery disease (CAD). Combining SIIRI with traditional risk factors improves MACE prediction accuracy.
Area of Science:
- Cardiology
- Inflammation Research
- Biomarker Discovery
Background:
- Coronary artery disease (CAD) poses a significant global health burden.
- Novel inflammatory markers are being investigated for their prognostic value in CAD.
- Lymphocyte-based inflammatory markers offer potential insights into CAD pathogenesis and progression.
Purpose of the Study:
- To evaluate six novel lymphocyte-based inflammatory markers for predicting major adverse cardiovascular events (MACEs) in newly diagnosed CAD patients.
- To determine the independent predictive value of these markers, including the Systemic Immune Inflammation Response Index (SIIRI) and Platelet-Lymphocyte Ratio (PLR).
- To assess the incremental predictive ability of these markers when added to traditional cardiovascular risk factors.
Main Methods:
- A cohort of 959 patients with newly diagnosed CAD was enrolled.
- Patients were followed for MACEs (cardiovascular death, myocardial infarction, stroke).
- Cox regression analysis was used to evaluate the association between inflammatory markers and MACEs.
Main Results:
- During follow-up, 23.9% of patients experienced MACEs.
- The Systemic Immune Inflammation Response Index (SIIRI) and Platelet-Lymphocyte Ratio (PLR) were identified as independent predictors of MACEs.
- SIIRI demonstrated superior predictive performance, significantly improving model discrimination and reclassification compared to traditional risk factors alone.
Conclusions:
- SIIRI is an independent and superior predictor of MACEs in newly diagnosed CAD patients.
- The integration of SIIRI with traditional risk factors enhances the accuracy of MACE prediction.
- SIIRI represents a promising novel biomarker for risk stratification in CAD management.
Background:
This study aimed to evaluate six novel lymphocyte-based inflammatory markers (neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio, platelet-lymphocyte ratio [PLR], systemic immune inflammation index [SII], systemic inflammatory response index, and systemic immune inflammation response index [SIIRI]) in patients with newly diagnosed coronary artery disease [CAD].
Methods:
A total of 959 patients newly diagnosed with CAD and underwent diagnostic coronary angiography were enrolled in this study and followed for major adverse cardiovascular events (MACEs), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The best cutoff value was used to compare the six indicators. Cox risk regression analysis evaluated the relationship between novel lymphocyte-based inflammatory markers and MACEs in newly diagnosed CAD patients.
Results:
During a mean follow-up period of 33.3 ± 9.9 months, 229 (23.9%) MACEs were identified. Multivariate Cox regression analysis showed that only SIIRI (hazard ratio [HR]: 5.853; 95% confidence interval [CI]: 4.092-8.371; p < .001) and PLR (HR: 1.725; 95% CI: 1.214-2.452; p = .002) were independent predictors of MACEs. Nevertheless, following the adjustment for covariates, only the SIIRI was found to be a significant predictor MACEs and its corresponding specific endpoint occurrences. The predictive ability of the model was improved when six different inflammatory markers were added to the basic model established by traditional risk factors, namely, the C-index increased, and the SIIRI increased most significantly (AUC: 0.778; 95% CI: 0.743-0.812; p < .001). However, among the six novel inflammatory markers, only SIIRI had improved net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (NRI: 0.187; 95% CI: 0.115-0.259, p < .001. IDI: 0.135; 95% CI: 0.111-0.159, p < .001), which was superior to the basic model established by traditional risk factors.
Conclusions:
SIIRI is independent predictor of MACEs in newly diagnosed CAD patients. SIIRI was superior to other measures in predicting MACEs. The combination of SIIRI and traditional risk factors can more accurately predict MACEs.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Related Concept Videos
Myocarditis I: Introduction
Coronary Artery Disease I: Introduction
Acute Coronary Syndrome III: Diagnostic studies
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis II: Clinical features and Diagnostic Tests
Coronary Artery Disease II: Pathophysiology